This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carlsten, M. Articles by Malmberg, K.-J. Search for Related Content PubMed PubMed Citation Articles by Carlsten, M. Articles by Malmberg, K.-J.

DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer Cells

¹ Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge; ² Immune and Gene Therapy Laboratory, Cancer Center Karolinska, Department of Oncology and Pathology, Karolinska Institutet; ³ Department of Obstetrics and Gynecology, Karolinska University Hospital Solna, Stockholm, Sweden and ⁴ Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands

Requests for reprints: Karl-Johan Malmberg, Center for Infectious Medicine, F59, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden. Phone: 46-8-58589688; Fax: 46-8-7466280; E-mail: kalle.malmberg{at}ki.se.

Although natural killer (NK) cells are well known for their ability to kill tumors, few studies have addressed the interactions between resting (nonactivated) NK cells and freshly isolated human tumors. Here, we show that human leukocyte antigen class I^low tumor cells isolated directly from patients with advanced ovarian carcinoma trigger degranulation by resting allogeneic NK cells. This was paralleled by induction of granzyme B and caspase-6 activities in the tumor cells and significant tumor cell lysis. Ovarian carcinoma cells displayed ubiquitous expression of the DNAX accessory molecule-1 (DNAM-1) ligand PVR and sparse/heterogeneous expression of the NKG2D ligands MICA/MICB and ULBP1, ULBP2, and ULBP3. In line with the NK receptor ligand expression profiles, antibody-mediated blockade of activating receptor pathways revealed a dominant role for DNAM-1 and a complementary contribution of NKG2D signaling in tumor cell recognition. These results show that resting NK cells are capable of directly recognizing freshly isolated human tumor cells and identify ovarian carcinoma as a potential target for adoptive NK cell–based immunotherapy. [Cancer Res 2007;67(3):1317–25]

This article has been cited by other articles:

				M. Carlsten, H. Norell, Y. T. Bryceson, I. Poschke, K. Schedvins, H.-G. Ljunggren, R. Kiessling, and K.-J. Malmberg Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells J. Immunol., October 15, 2009; 183(8): 4921 - 4930. [Abstract] [Full Text] [PDF]

				W. Maat, A. R. van der Slik, D. H. J. Verhoeven, B. Z. Alizadeh, L. V. Ly, W. Verduijn, G. P. M. Luyten, A. Mulder, T. van Hall, F. Koning, et al. Evidence for Natural Killer Cell-Mediated Protection from Metastasis Formation in Uveal Melanoma Patients Invest. Ophthalmol. Vis. Sci., June 1, 2009; 50(6): 2888 - 2895. [Abstract] [Full Text] [PDF]

				A. Soriani, A. Zingoni, C. Cerboni, M. L. Iannitto, M. R. Ricciardi, V. Di Gialleonardo, M. Cippitelli, C. Fionda, M. T. Petrucci, A. Guarini, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype Blood, April 9, 2009; 113(15): 3503 - 3511. [Abstract] [Full Text] [PDF]

				A. Iguchi-Manaka, H. Kai, Y. Yamashita, K. Shibata, S. Tahara-Hanaoka, S.-i. Honda, T. Yasui, H. Kikutani, K. Shibuya, and A. Shibuya Accelerated tumor growth in mice deficient in DNAM-1 receptor J. Exp. Med., December 22, 2008; 205(13): 2959 - 2964. [Abstract] [Full Text] [PDF]

				E. Alici, T. Sutlu, B. Bjorkstrand, M. Gilljam, B. Stellan, H. Nahi, H. C. Quezada, G. Gahrton, H.-G. Ljunggren, and M. S. Dilber Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components Blood, March 15, 2008; 111(6): 3155 - 3162. [Abstract] [Full Text] [PDF]

				G. B. Scott, J. L. Meade, and G. P. Cook Profiling killers; unravelling the pathways of human natural killer cell function Brief Funct Genomic Proteomic, January 21, 2008; (2008) elm037v1. [Abstract] [Full Text] [PDF]

				A. Barber, T. Zhang, and C. L. Sentman Immunotherapy with Chimeric NKG2D Receptors Leads to Long-Term Tumor-Free Survival and Development of Host Antitumor Immunity in Murine Ovarian Cancer J. Immunol., January 1, 2008; 180(1): 72 - 78. [Abstract] [Full Text] [PDF]

				Y. M. El-Sherbiny, J. L. Meade, T. D. Holmes, D. McGonagle, S. L. Mackie, A. W. Morgan, G. Cook, S. Feyler, S. J. Richards, F. E. Davies, et al. The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells Cancer Res., September 15, 2007; 67(18): 8444 - 8449. [Abstract] [Full Text] [PDF]